Abstract
The manufacturers' descriptions for immunoassays for the detection of benzodiazepines in urine suggest that all therapeutically used benzodiazepines are detected equally. It is unlikely that the different molecular structures do not influence the results of pertinent measurements. Therefore, the cross-reactivity of 35 benzodiazepines and benzodiazepine-metabolites was determined with the TDx-system. As compared to nordiazepam all compounds--except diazepam--had a reduced cross-reactivity. In order to get a TDx result equal to or exceeding 200 ng/ml nordiazepam-equivalents, high benzodiazepine concentrations in urine are required in some cases. These high concentrations are not obtained in the therapeutic range of application. These considerations can be applied to other immunoassays like RIA and EMIT.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
